Table 2.

CDK4/6 Inhibitor with Androgen Signaling Inhibitor Combination Trials

	Patient Population	Status	Identifier	Estimated Primary Completion
ADT ± Palbociclib, Phase II	mHSPC, RB-positive	Completed	NCT02059213	9/9/2017
Palbociclib, phase II	mCRPC	Recruiting	NCT02905318	11/2020
Enzalutamide ±Ribociclib, Phase IB/II	mCRPC chemo-naïve that retain RB expression	Recruiting	NCT02555189	4/14/2020
Ribociclib + Docetaxel, Phase, Phase Ib/II	mCRPC	Recruiting	NCT02494921	12/31/2019
Abiraterone ± Abemaciclib, Phase II	mCRPC	Recruiting	NCT03706365	9/15/2021